Samantha Medwid1,2
Hayley R. Price1
Daniel P. Taylor1
Jaymie Mailloux1,2Ute I. Schwarz1,2Richard B. Kim1,2,3
Rommel G. Tirona1,2*- 1Department of Physiology & Pharmacology, University of Western Ontario, London, ON, Canada
- 2Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, London, ON, Canada
- 3Department of Oncology, Schulich School of Medicine, University of Western Ontario, London, ON, Canada
Organic anion transporting polypeptide 2B1 (OATP2B1, gene SLCO2B1) is an uptake transporter that is thought to determine drug disposition and in particular, the oral absorption of medications. At present, the clinical relevance of SLCO2B1 genetic variation on pharmacokinetics is poorly understood. We sought to determine the functional activity of 5 of the most common missense OATP2B1 variants (c.76_84del, c.601G>A, c.917G>A, c.935G>A, and c.1457C>T) and a predicted dysfunctional variant (c.332G>A) in vitro. Furthermore, we measured the basal plasma concentrations of endogenous OATP2B1 substrates, namely estrone sulfate, dehydroepiandrosterone sulfate (DHEAS), pregnenolone sulfate, coproporphyrin I (CPI), and CPIII, and assessed their relationships with SLCO2B1 genotypes in 93 healthy participants. Compared to reference OATP2B1, the transport activities of the c.332G>A, c.601G>A and c.1457C>T variants were reduced among the substrates examined (estrone sulfate, DHEAS, CPI, CPIII and rosuvastatin), although there were substrate-dependent effects. Lower transport function of OATP2B1 variants could be explained by diminished cell surface expression. Other OATP2B1 variants (c.76-84del, c.917G>A and c.935G>A) had similar activity to the reference transporter. In the clinical cohort, the SLCO2B1 c.935G>A allele was associated with both higher plasma CPI (42%) and CPIII (31%) concentrations, while SLCO2B1 c.917G>A was linked to lower plasma CPIII by 28% after accounting for the effects of age, sex, and SLCO1B1 genotypes. No association was observed between SLCO2B1 variant alleles and estrone sulfate or DHEAS plasma concentrations, however 45% higher plasma pregnenolone sulfate level was associated with SLCO2B1 c.1457C>T. Taken together, we found that the impacts of OATP2B1 variants on transport activities in vitro were not fully aligned with their associations to plasma concentrations of endogenous substrates in vivo. Additional studies are required to determine whether circulating endogenous substrates reflect OATP2B1 activity.
Introduction
Organic anion transporting peptide 2B1 (OATP2B1, previously known as OATP-B, gene name SLCO2B1) is a member of the solute transporting carrier (SLC) superfamily. OATP2B1 is involved in the cellular uptake of a wide variety of drugs including 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-Co-A) reductase inhibitors and fexofenadine (Kobayashi et al., 2003; Nozawa et al., 2004), as well as endogenous compounds such as steroid hormone conjugates (estrone sulfate, dehydroepiandrosterone sulfate (DHEAS), and pregnenolone sulfate), coproporphyrins (CP) and thyroid hormones (Tamai et al., 2000; Kullak-Ublick et al., 2001; Pizzagalli et al., 2003; Grube et al., 2006a; Bednarczyk and Boiselle, 2016; Shen et al., 2016; Meyer Zu Schwabedissen et al., 2018). OATP2B1 is ubiquitously expressed throughout the body in organs including intestine, liver, kidney, brain, heart, skeletal muscle, lung, placenta, pancreas and macrophages (Tamai et al., 2000; Kullak-Ublick et al., 2001; St-Pierre et al., 2002; Grube et al., 2006b; Niessen et al., 2009; Seki et al., 2009; Knauer et al., 2010; Hussner et al., 2015; Kim M. et al., 2017; Nakano et al., 2019). It is generally appreciated that intestinal OATP2B1 is involved in the oral absorption of medications as its inhibition by fruit juices is thought to reduce the bioavailability of substrate drugs including fexofenadine and celiprolol in humans (Dresser et al., 2002; Lilja et al., 2003). Indeed, pharmacokinetic studies in OATP2B1 knockout mice convincingly revealed a role of this transporter in the oral absorption of some substrate drugs, as well as a target of food- and drug-drug interactions (Medwid et al., 2019; Chen et al., 2020). Although there is significant experimental support for the relevance of intestinal OATP2B1 to drug absorption (McFeely et al., 2019), the impact of this transporter on drug distribution and elimination in other tissues where it is also expressed, remains significantly less understood (Kinzi et al., 2021).
Genetic variations and in particular, nonsynonymous single nucleotide variants (SNV) in drug transporters can be responsible for interindividual differences in drug response (Yee et al., 2018). Indeed, a SNV in the liver-specific OATP1B1 transporter (SLCO1B1 c.521T>C), has become an established clinical pharmacogenetic marker that predicts systemic drug exposure (Niemi et al., 2011) and in some instances, treatment outcomes (SEARCH Collaborative Group et al., 2008; Trevino et al., 2009). For the most part, in vitro studies have consistently shown that the OATP1B1 c.521T>C (*5) variant has reduced activity (Tirona et al., 2001), which is mechanistically in keeping with the well-recognized influence on clinical pharmacokinetics and drug responses. In contrast, the pharmacological and therapeutic relevance of SLCO2B1 genetic variation is less clear despite numerous clinical and in vitro studies examining the potential impacts.
Associations between the pharmacokinetics or responses of OATP2B1 substrate drugs for the most common SLCO2B1 missense SNVs, c.935G>A and c.1457C>T (global mean allelic frequencies of 17.6 and 8.6%, respectively), have been reported in many studies, however their results have not always been consistent. For instance, with the most common SLCO2B1 c.935G>A variant (*3 allele), montelukast plasma concentrations were lower in participants carrying the variant allele in some studies (Mougey et al., 2009; Mougey et al., 2011) but not others (Kim et al., 2013; Tapaninen et al., 2013). The SLCO2B1 c.935G>A variant did not associate with plasma rosuvastatin concentrations in some studies (DeGorter et al., 2013; Kim TE. et al., 2017), although this genetic marker was linked to reduced lipid lowering effects. (Kim TE. et al., 2017). In prostate cancer patients undergoing androgen deprivation therapy, SLCO2B1 c.935G>A variant carriers were compellingly shown to have shorter time to progression in different cohorts (Yang et al., 2011; Fujimoto et al., 2013; Wang et al., 2016; Hahn et al., 2019).
With respect to the SLCO2B1 c.1457C>T variant allele and pharmacokinetic associations, contradicting studies have also been reported. For example, the SLCO2B1 c.1457C>T variant was associated with having higher, lower or no impact on systemic exposures of fexofenadine (Akamine et al., 2010; Imanaga et al., 2011; Kashihara et al., 2017). Moreover, in one study the SLCO2B1 c.1457C>T variant was linked to lower circulating concentrations of celiprolol (Ieiri et al., 2012) but no association was observed in another report (Kashihara et al., 2017). In a recent study, 22% lower concentration of the 3S-5R-fluvastatin enantiomer was observed in subjects with the SLCO2B1 c.1457C>T variant, per allele (Hirvensalo et al., 2019).
In vitro studies have similarly provided heterogeneous results for the transport activity of OATP2B1 genetic variants. The OATP2B1 c.935G>A variant has mostly been associated with reduced transport activity, but its functional impact appears to be highly substrate- and experimental model-dependent (Nozawa et al., 2002; Ho et al., 2006; Yang et al., 2011; Nies et al., 2013; Yang et al., 2020). With the OATP2B1 c.1457C>T variant, in vitro studies are also conflicting with some reporting reduced transport activity (Nozawa et al., 2002; Nies et al., 2013), while for others, there was enhanced function (Ho et al., 2006; Yang et al., 2020), again with substrate-dependent effects. Taken together, because of all the divergent and inconsistent findings from clinical and biochemical studies, the potential impacts of SLCO2B1 genetic variation to transporter activity remains to be understood.
The circulating concentrations of certain endogenous drug transporter substrates have become clinical biomarkers of transporter activity, especially in the context of predicting altered pharmacokinetics with drug-drug interactions and disease states (Rodrigues and Rowland, 2019). Indeed, coproporphyrin I (CPI) is a validated endogenous biomarker of OATP1B (OATP1B1 and OATP1B3) activity (Lai et al., 2016; Shen et al., 2016). Interestingly however, is that individuals homozygous for the reduced function SLCO1B1 c.521T>C variant have about 2-fold higher baseline plasma CPI concentrations (Yee et al., 2018; Mori et al., 2019; Suzuki et al., 2021). Furthermore, there is 1.4-fold higher plasma estrone sulfate concentration in carriers of the SLCO1B1 c.521T>C variant allele (van der Deure et al., 2008). These findings with SLCO1B1 raise the possibility that the in vivo relevance of SLCO2B1 genetic variation can be addressed by examining the concentrations of its circulating endogenous substrates.
In this report, we evaluated the in vitro transport activity of the most common OATP2B1 genetic variants in global populations [c.935G>A (*3), c.1457C>T, c.76_84del, c.917G>A, and c.601G>A] with the motivation of clarifying whether these cause functional effects. Furthermore, we explored the possibility that genetic variations in SLCO2B1 are associated with the plasma concentrations of its endogenous substrates, namely, estrone sulfate, DHEAS, pregnenolone sulfate, CPI and CPIII. Our key findings are that circulating CPI and CPIII concentrations are greater in healthy individuals carrying the common SLCO2B1 c.935G>A variant allele. However, there was a lack of significant impact of the OATP2B1 c.935G>A variant on substrate transport activity when tested in vitro.
Materials and Methods
Reagents
Rosuvastatin, d5-estrone sulfate, d5-DHEAS, 15N4-CPI, d8-CPIII and d6-rosuvastatin were purchased from Toronto Research Chemicals (Toronto, ON, Canada). CPI and CPIII were obtained from Frontier Specialty Chemicals (Logan, UT, United States). All other chemicals, unless otherwise stated, were obtained from Sigma-Aldrich (St. Louis, MO).
Variant OATP2B1 Plasmid Construction
hOATP2B1 reference sequence in pcDNA3.1 (Invitrogen, Carlsbad, CA, United States) expression plasmid was prepared using methods outlined previously (Tirona et al., 2003). OATP2B1 variant expression plasmids were created using QuikChange II site-directed mutagenesis kit (Agilent Technologies; Santa Clara, CA, United States) and primers found in Supplementary Table S1, following manufacturer’s protocol. Reference OATP2B1 sequence and presence of polymorphisms were verified by Sanger sequencing.
Transient Overexpression of OATP2B1 and Variants in Cultured Cells
Human embryonic kidney type T (HEK293T) cells were purchased from American Type Culture Collection (Manassas, VA, United States) for use in transient transfection studies. HEK293 cells are routinely used in drug transporter studies as they are efficiently transfected and express relatively low basal expression of drug transporters (Ahlin et al., 2009). Previous studies which examined the transport function of OATP2B1 genetic variants have used the HEK293 cell line for transporter overexpression (Nozawa et al., 2002; Nies et al., 2013; Yang et al., 2020). HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Scientific, Grand Island, NY, United States) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 2 mM L-glutamine (Invitrogen), at 37°C, 5% CO2. For HEK293T cell transport experiments, cells were grown on poly-L-lysine-coated 24-well plates. After 24 h, cells were transfected with blank insert expression plasmids (vector control) or expression plasmids containing transporter cDNA inserts (1 µg DNA/well) using Lipofectamine 3000 (Invitrogen), according to our previously described method (Medwid et al., 2019). Cells were incubated with transfection plasmids for 16 h prior to experiments.
Solute Transport by Reference OATP2B1 and Variants in Vitro
HEK293T cells were plated onto 24-well culture plates for solute uptake experiments. Estrone sulfate, DHEAS, CPI, CPIII or rosuvastatin (each at 1 μg/ml final concentration) was dissolved in modified Krebs-Henseleit buffer (KHB) (1.2 mM MgSO4, 0.96 mM KH2PO4, 4.83 mM KCl, 118 mM NaCl, 1.53 mM CaCl2, 23.8 mM NaHCO3, 12.5 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid, 5 mM glucose) at pH 6. Cultured cells were treated with substrates (200 µl) for 10–30 min at 37°C, 5% CO2. Thereafter, cells were washed three times rapidly with ice-cold phosphate-buffered saline (PBS). Cells were lysed using 200 µl of acetonitrile (for estrone sulfate, DHEAS, or rosuvastatin analyses) or 12 M formic acid (for CPI and CPIII analyses) spiked with internal standards (d5-estrone sulfate 100 ng/ml, d5-DHEAS 100 ng/ml, 15N4-CPI 100 nM, or d6-rosuvastatin 20 ng/ml). Cell lysates were centrifuged for 10 min at 13,500 rpm in a microcentrifuge and supernatants were dried in a SpeedVac (Thermo Fisher) at 45°C and resuspended in 100–200 µl mobile phase. Residues were analyzed for estrone sulfate, DHEAS, CPI, CPIII and rosuvastatin by liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods described below. The specific functional activity of transfected wildtype OATP2B1 and its variants were determined after subtraction of the cellular substrate uptake of blank vector control transfected cells.
Cell Surface Protein Biotinylation
After transfection of HEK293T cells, sulfo-NHS-SS-Biotin (Thermo Scientific) diluted 0.5 mg/ml/well in PBS containing 100 μM CaCl2 and 2.12 mM MgCl2 (PBS/Mg/Ca) was added to cells and incubated for 1 h at 4°C. Cells were then washed with ice-cold PBS/Mg/Ca containing 50 μM glycine (PBS/Mg/Ca/glycine) 3 times followed by a 20-min incubation with PBS/Mg/Ca/glycine. Cells were lysed in RIPA buffer [10 mM Tris, 150 mM NaCl, 1.27 mM EDTA, 0.1% (w/v) SDS, and 10% (v/v) Triton X-100] containing protease inhibitors and cell lysate was sonicated. Streptavidin-agarose (Thermo Scientific) was added to a proportion of cells and rocked for 1 h at room temperature. The remaining cell lysate in RIPA buffer was used to determine total protein concentrations. Streptavidin-agarose samples were then centrifuged for 3 min at 18,000 g and the pellet washed 3 times with ice-cold RIPA buffer. Pellets were subsequently rocked with 4X LDS sample buffer (Invitrogen) containing 5% 2-β-mercaptoethanol and protease inhibitors for 30 min. Thereafter, samples were centrifuged and supernatant was collected and stored until sodium dodecylsulfate - polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting.
Western Blot
Cell surface biotinylated and total protein samples were analyzed by SDS-PAGE using 4–12% gradient gels (NuPage, Invitrogen). After transfer to polyvinylidene difluoride membranes, blots were probed with human OATP2B1 (Cat. No. H-189, Santa Cruz, Dallas, TX), GAPDH (Cat. No. sc-4772, Santa Cruz) or Na+/K+ ATPase (Cat. No. 3010S, Cell Signalling, Danvers, MA, United States) and visualized using horseradish-peroxidase labeled anti-mouse or anti-rabbit antibodies (Cell Signaling) and chemiluminescence reagent (Amersham ECL Select, GE Healthcare) on an ImageQuant LAS 500 (GE Healthcare, Mississauga, ON, Canada).
Participants and Plasma Samples
Morning (∼8 am) blood samples were obtained after overnight fast from 93 healthy participants recruited from previously reported studies (Woolsey et al., 2016; McLean et al., 2018; Tirona et al., 2018). These studies were approved by the Human Research Ethics Board at University of Western Ontario (London, ON, Canada) and all participants provided informed written consent. Participant demographics can be found in Table 3.
Liquid Chromatography-Tandem Mass Spectrometry
Estrone Sulfate, Pregnenolone Sulfate and DHEAS Assay. Plasma samples (100 μl) were combined with internal standard solution (300 μl) containing d5-estrone sulfate (100 ng/ml) and d5-DHEAS (100 ng/ml) in acetonitrile. Samples were vortexed and centrifuged at 13,000 g and 4°C for 15 min. The resulting supernatant was transferred to a microcentrifuge tube for drying in a SpeedVac. The residue was reconstituted in mobile phase (100 μl) containing 0.1% ammonium hydroxide in water and 0.1% ammonium hydroxide (90%/10%) for injection into the liquid chromatograph. Analytes were separated by liquid chromatography (Agilent 1200; Agilent; San Clara, CA, United States) using a Hypersil Gold column (50 × 3 mm, 5 μm, Thermo Fisher Scientific) following 60 µl sample injection. A mobile phase of 0.1% v/v ammonium hydroxide in water (A) and 0.1% v/v ammonium hydroxide in acetonitrile (B) was used, with an elution gradient of 10% B from 0–1.0 min, 10–90% B from 1.0–4.5 min, 90% B from 4.5–5.25 min, 90–10% B from 5.25–5.8 min and 90% B from 5.8–6.0 min, for a run time of 6 min and flow rate of 0.5 ml/min. The heated electrospray ionization source of the triple quadrupole mass spectrometer (Thermo TSQ Vantage; Thermo Fisher Scientific) was operated in negative mode (4000 V, 350°C) with collision energy set at 25 V. Additional ionization source conditions used were as follows: 40 arbitrary units for sheath gas pressure, 15 arbitrary units for auxiliary gas pressure and 350°C for capillary temperature. Selected reaction monitoring for estrone sulfate, d5-estrone sulfate, DHEAS, d5-DHEAS, and pregnenolone sulfate was performed using mass transitions 349.2→268.3 m/z, 354.1→273.4 m/z, 367.1→97.0 m/z, 372.1→98.0 m/z, and 395.1→97.0 m/z, respectively. Estrone sulfate/d5-estrone sulfate, DHEAS/d5-DHEAS and pregnenolone sulfate had retention times of 2.84, 2.91, and 3.13 min, respectively. Calibration samples containing estrone sulfate 0–4 ng/ml, pregnenolone sulfate 0–4,000 ng/ml and DHEAS 0–4,000 ng/ml were prepared in PBS from ethanol stock solutions and processed similarly as above.
CPI and CPIII Assay. CPI concentrations were measured according to a published method (Lai et al., 2016) with modifications. Plasma samples (200 μl) were combined with internal standard solution (100 μl) containing d8-CPIII 1.5 μmol/ml in 12 M formic acid. Ethyl acetate (1 ml) was combined, and samples were vortexed for 1 min and centrifuged at 13,000 g and 4°C for 15 min. The resulting organic layer (760 μl) was transferred to a microcentrifuge tube for drying in a SpeedVac. The residue was reconstituted in mobile phase (100 μl) containing 0.1% formic acid in water and 0.1% formic acid in acetonitrile (80%/20%) for injection into the liquid chromatograph. Solutes were separated on a Zorbax Eclipse Plus C18 column (100 mm × 2.1 mm, 1.8 μm). A mobile phase of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) was used, with an elution gradient of 20% B from 0–0.5 min, 20–71% B from 0.5–9 min, 71–98% B from 9–10 min, 98% B from 10–10.25, 98–20% B from 10.25-5–11.25 min and 20% B from 11.25–12.5 min, for a run time of 12.5 min and flow rate of 0.2 ml/min. Mass spectrometry detection was carried out on a TSQ Vantage triple-quadrupole instrument set in positive mode for detection of CPI/CPIII, d8-CPIII and 15N4-CPI with transitions 655.4 → 596.4 m/z, 659.3 → 600.3 m/z and 663.0 → 602.4 m/z. CPI/15N4-CPI and CPIII/d8-CPIII eluted at 8.29 and 8.54 min, respectively. Calibration samples containing CPI 0–10 nM and CPIII 0–1 nM were prepared in PBS from DMSO stock solutions and processed similarly as above. All experiments and analytical procedures involving CPI and CPIII were performed under low light conditions.
Rosuvastatin Assay. Analytes were separated by liquid chromatography using Hypersil Gold (50 × 3 mm, 5 µm) following 50 µl sample injection. A mobile phase of 0.1% v/v formic acid in water (A) and 0.1% v/v formic acid in acetonitrile (B) was used, with an elution gradient of 25% B from 0–1.0 min, 25–40% B from 1.0–6.0 min, 40–25% B from 6.0–7.0 min, and 25% B from 7.0–8.0 min, for a run time of 8 min and flow rate of 0.5 ml/min. The heated electrospray ionization source of the TSQ Vantage triple-quadrupole mass spectrometer was operated in positive mode (4500 V, 350°C) with collision energy set at 25 V. Additional ionization source conditions used were as follows: 40 arbitrary units for sheath gas pressure, 15 arbitrary units for auxiliary gas pressure and 350°C for capillary temperature. Selected reaction monitoring for rosuvastatin and d6-rosuvastatin was performed using mass transitions 482.1→258.2 m/z, and 488.0→264.3 m/z, respectively. Rosuvastatin and d6-rosuvatatin had a retention time of 4.6 min.
Genotyping
Volunteers were genotyped by TaqMan allelic discrimination assay (Applied Biosystems, Foster City, CA, United States) for SLCO2B1 c.76_84del (rs72408262; C_99453792_10), SLCO2B1 c.601G>A (rs35199625; C_25606765_20), SLCO2B1 c.917G>A (rs78825186; C_105413676_20), SLCO2B1 c.935G>A rs12422149; C_3101331_10), SLCO2B1 c.1457C>T (rs2306168; C_16193013_20), SLCO1B1 c.388A>G (rs2306283; C_1901697_20), SLCO1B1 c.521C>T (rs4149056; C_30633906_10), ABCG2 (Breast Cancer Resistance Protein, BCRP) c.421>A (rs2231141; C_15854163_70), CYP (Cytochrome P450) 2C9*2 (rs1799853; C_25625805_10), CYP2C9*3 (rs1057910; C_27104891_10), ABCC2 (Multidrug Resistance Protein 2, MRP2) c.1249G>A (rs2273697; C_22272980_20) and ABCC2 c.-24C>T (rs717620; C_2814642_10).
Statistics
Unpaired, two-tailed, student’s t-test was used to assess differences between the transport activities of variants and reference OATP2B1. Univariate analysis with unpaired student’s t-test was used to compare plasma endogenous OATP2B1 substrate concentrations among wildtype and variant carriers (heterozygous and homozygous). Multiple linear regression was used to determine the contributions of participant genotypes and demographic variables to the log-transformed plasma endogenous OATP2B1 substrate concentrations. A priori statistical significance was set at a p-value of <0.05. All statistical analysis was conducted using GraphPad Prism 9 (La Jolla, CA, United States).
Results
Transport Activity of OATP2B1 Genetic Variants
We selected the five most common nonsynonymous OATP2B1 genetic variants with global allelic frequencies greater than 1% for in vitro functional assessment: c.76_84del, c.601G>A, c.917G>A, c.935G>A, and c.1457C>T (Table 1; Figure 1). Predicted deleteriousness or pathogenicity for the common OATP2B1 genetic variants based on computational ensemble models are shown in Table 1. The Combined Annotation Dependent Depletion (CADD) scores range in value from 0 to 100, with greater values reflecting higher probability of deleteriousness of a variant. The Rare Exom Variant Ensemble Learner (REVEL) and Meta-Logistic-Regression (MetaLR) models provide scores with values ranging from 0 to 1, with higher values predicting pathogenicity/deleteriousness. We included another rare genetic variant, OATP2B1 c.332G>A (global allelic frequency 0.0014) in the in vitro study as a potential positive (deleterious) control with high CADD, REVEL and MetaLR scores (Table 1). The OATP2B1 c.601G>A variant was the only other variant that the in silico models predict to be potentially deleterious/pathogenic. The transport activities of the OATP2B1 variants were determined by assessing cellular accumulation of the endogenous substrates estrone sulfate, DHEAS, CPI, CPIII as well as the substrate drug rosuvastatin, in transiently transfected cells. OATP2B1-mediated cellular accumulation of substrates was evidenced by 9.5-, 1.5-, 2.0-, 5.2- -and 6.5-fold greater cellular uptake for estrone sulfate, DHEAS, CPI, CPIII and rosuvastatin, respectively, when compared to blank vector control cells (Figure 2). The following summarizes the OATP2B1 variants with altered transport compared to wildtype according to substrate. OATP2B1-mediated estrone sulfate transport was significantly lower with OATP2B1 variants c.332G>A (79.2%) and c.1457C>T (29.3%) (Figure 2A). The variants c.332G>A, c.601G>A and c.1457C>T had lower OATP2B1-mediated DHEAS cellular accumulation by 43.4, 45.9 and 45.1%, respectively (Figure 2B). OATP2B1-mediated CPI uptake was lower by 75.9% with the c.1457C>T variant compared to reference (Figure 2C). For CPIII, there was lower OATP2B1-mediated transport for variants c.76-84del (18.2%), c.332G>A (77.4%), c.601G>A (32.5%), c.1457C>T (45.6%) compared to reference (Figure 2D). OATP2B1 c.76-84del had greater OATP2B1-mediated rosuvastatin cellular accumulation by 25%, while c.332G>A, c.601G>A, c.935G>A and c.1457C>T had lower transporter-mediated rosuvastatin cellular accumulation by 28.3, 45.0, 9.9, and 31.6%, respectively (Figure 2E). Across all substrates, the OATP2B1 c.1457C>T variant was found to have reduced transport activity compared to OATP2B1 reference. Lower transport activity was also generally observed for the OATP2B1 c.332G>A and c.601G>A variants, however, this was not statistically significant for all substrates. Overall, the OATP2B1 c.76-84del, c.917G>A and c.935G>A variants were not particularly different in transport activity compared to the reference transporter.
TABLE 1. SLCO2B1 SNVs studied and their allele frequencies.
FIGURE 1. Predicated 2-D structure of OATP2B1 full length transcriptional variant. Genetic variants of interest are highlighted in red and indicated by arrows with residue number and amino acid change. The predicted 2-dimensional membrane topology model of OATP2B1 was generated using Protter interactive protein visualization software (https://wlab.ethz.ch/protter/start/).
FIGURE 2. In vitro transport activity of OATP2B1 genetic variants with substrates. Cellular accumulation of (A) estrone sulfate, (E1S) (1 μg/ml, n = 3), (B) dehydroepiandrosterone sulfate (DHEAS) (1 μg/ml, n = 4), (C) coproporphyrin (CP) I (1 μg/ml, n = 3), (D) CPIII (1 μg/ml, n = 3) and (E) rosuvastatin (1 μg/ml, n = 3) in HEK293T cells were transiently transfected with vector control (VC), OATP2B1 reference and OATP2B1 variants after incubation for 10 min (E1S, DHEAS, CPIII and rosuvastatin) or 30 min (CPI) in Krebs-Henseleit buffer (KHB) at pH 6. Results are shown as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
Estrone Sulfate and CPIII Transport Kinetics by OATP2B1 Genetic Variants
OATP2B1-mediated transport kinetics were further evaluated for the nonsynonymous variants with estrone sulfate and CPIII. Correcting for cellular accumulation of solutes in the vector control cells, the maximal uptake rates (Vmax), affinities (Km) and estimated uptake clearance (Vmax/Km) for OATP2B1 reference and variants are shown in Table 2. With estrone sulfate transport, the Vmax and Km values for OATP2B1 variants c.332G>A and c.1457C>T could not be determined as saturable kinetics were not evident. Assuming non-saturable, linear OATP2B1 transport, the c.332G>A and c.1457C>T variants had markedly reduced uptake clearance than reference OATP2B1. For CPIII, the OATP2B1 c.332G>A variant had clearly altered transport kinetics compared to reference OATP2B1, with a reduction of Vmax by 73%.
TABLE 2. Estrone Sulfate and CPIII transport kinetics by OATP2B1 and its genetic variants.
Cell Surface Expression of OATP2B1 Variants
Total and cell surface protein expression of OATP2B1 reference and variants in transfected HEK293T cells were examined by western blot. Cell-surface expression of OATP2B1 was absent in blank vector transfected HEK293T cells (Supplementary Figure S1). When normalized to Na+/K+ ATPase, cell surface protein expression of OATP2B1 c.332G>A, c.601G>A, c.935G>A and c.1457C>T were decreased significantly by 51, 72, 37, and 83% compared to OATP2B1 reference, respectively (Figure 3; Supplementary Figure S1).
FIGURE 3. Protein expression of OATP2B1 genetic variants. Representative western blots of (A) cell surface and (B) total OATP2B1 protein expression in HEK293T cells transfected with OATP2B1 reference and OATP2B1 genetic variants. Western blot analysis of surface OATP2B1 protein expression was normalized to Na+/K+ ATPase. Results are shown as mean ± SEM (n = 3), *p < 0.05, **p < 0.01.
Study Cohort for Circulating OATP2B1 Substrates
Plasma samples were obtained from 93 healthy volunteers for analysis. The median age was 25, 40.9% were male and the mean weight was 69.8 kg. Of the 93 participants, 69 were Caucasian, 20 East Asian, and 4 African. Allelic frequencies of each SLCO2B1 variant in the cohort were 0.027, 0.016, 0.027, 0.123, and 0.118 for c.76-84del, c.601G>A, c.917G>A, c.935G>A and c.1457C>T, respectively (Table 3). No deviations from Hardy-Weinberg were seen for SLCO2B1 genotypes. The allelic frequencies for SLCO2B1 variants in the study cohort differed by race (Table 3) and were comparable to that reported in the Genome Aggregation Database (gnomAD) database (Karczewski et al., 2020) (Table 1). For example, the SLCO2B1 c.935G>A and c.1457C>T variants were more frequent in East Asian than Caucasian participants (Table 3).
TABLE 3. Study participant demographics (n = 93).
Effects of Demographic Factors on Plasma Endogenous OATP2B1 Substrate Concentrations
Median plasma concentrations (range) of estrone sulfate, DHEAS, pregnenolone sulfate, CPI and CPIII were 0.73 ng/ml (0.04–3.74 ng/ml), 1826 ng/ml (82–6,515 ng/ml), 52.1 ng/ml (9.4–112.3 ng/ml), 0.92 nM (0.29–3.25 nM) and 0.12 nM (0.04–0.21 nM), respectively (Figure 4). Univariate analyses were performed to compare OATP2B1 endogenous substrate concentrations with demographic factors (age, sex, race). Estrone sulfate concentrations were not associated with age, sex, or race (Figure 4A). Lower DHEAS concentrations were observed with increasing age as was for female compared to male sex, and for Caucasian compared to East Asian race (Figure 4B). Similarly, younger age and male sex was associated with greater concentrations of pregnenolone sulfate (Figure 4C). Lastly, CPI and CPIII concentrations were not associated with age, however, the levels of both compounds were greater in males compared to females, and in East Asians compared to Caucasians (Figures 4D,E).
FIGURE 4. Cohort distribution of endogenous biomarkers levels by baseline demographics. Frequency distribution of (A) estrone sulfate, (B) DHEAS, (C) pregnenolone sulfate (D) CPI and (E) CPIII. Association of endogenous substrates with age, sex, and ethnicity. Box and whiskers plots are shown as mean (line), 25th and 75th percentile (box) and range (whiskers) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Univariate Analysis of Genetic Variations on Plasma Endogenous OATP2B1 Substrate Concentrations
We examined whether SLCO2B1 variants c.76-84del, c.601G>A, c.917G>A, c.935G>A, and c.1457C>T were associated with plasma concentrations of OATP2B1 endogenous substrates. The SLCO2B1 variant c.332G>A was not genotyped in this cohort because the expected minor allelic frequency was less than 0.01% (Table 1). Pairwise comparisons showed greater plasma DHEAS (by 40%) and pregnenolone sulfate (by 57%) concentrations in participants carrying SLCO2B1 c.1457C>Talleles (Table 4). The SLCO2B1 c.935G>A allele was associated with higher plasma concentrations of CPI and CPIII by 43 and 46%, respectively (Table 4). Additionally, the SLCO2B1 c.917G>A allele was associated with a 33% lower CPIII plasma levels (Table 4).
TABLE 4. Univariate Analyses of SLCO2B1 gene variants with circulating endogenous substrate concentrations.
Since the OATP2B1 endogenous substrates (estrone sulfate, DHEAS, CPI or CPIII) measured in plasma are also substrates of other transporters (e.g., OATP1B1, MRP2 and BCRP) or subject to drug metabolism (e.g., CYP2C9), we examined their possible associations with common SNPs in these genes (Zhai et al., 2011; Dudenkov et al., 2017; Muller et al., 2018) by pairwise comparisons. SLCO1B1 c.388A>G was associated with higher pregnenolone sulfate levels (by 47%) but not significantly for estrone sulfate, DHEAS, CPI, or CPIII concentrations (Supplementary Table S2). Likewise, SLCO1B1 c.521T>C, ABCG2 (BCRP) c.421C>A, CYP2C9*2, CYP2C9*3, ABCC2 (MRP2) c.1248G>A and ABCC2 c.-24C>T were not significantly associated with any of the endogenous substrates investigated (Supplementary Table S2).
Multivariable Analysis of SLCO2B1 Genetic Variations on Plasma Endogenous OATP2B1 Substrate Concentrations
Multivariable linear regression analyses were performed to determine whether SLCO2B1 variant were associated with plasma concentrations of each of the OATP2B1 endogenous substrates. For each model, demographic variables were included such as sex, race and age, particularly when associations were found in univariate analyses. Furthermore, the clinically relevant SLCO1B1 c.388A>G and SLCO1B1 c.521C>T alleles were included into models because the measured solutes are also OATP1B1 substrates and for some solutes (e.g., estrone sulfate and CPI), associations with these genotypes have been previously reported. The final models with parameter estimates are shown in Table 5.
TABLE 5. Multivariable linear regression models for circulating endogenous substrates of OATP2B1.
In the model for estrone sulfate, there was an association of the SLCO1B1 c.521C>T allele with 62% higher plasma concentrations (p = 0.053) when the model was adjusted for sex and included other SLCO2B1/SLCO1B1 genotypes. It is notable that variables included in the model poorly explained the interindividual variability in circulating estrone sulfate as R2 was 0.047.
For DHEAS, 49% of variation in circulating concentrations could be explained by a model that includes the variables of sex, age, and SLCO2B1/SLCO1B1 genotypes. Sex and age were variables that were significantly associated with DHEAS concentrations. The model predicts males have 94% higher DHEAS concentrations, while advancing age results in decreasing plasma DHEAS, with a 22% lower level for each decade. Although SLCO2B1 c.1457C>T was associated with DHEAS concentrations in univariate analysis, this was no longer found when adjusting for sex and age.
About 45% of the variability in circulating pregnenolone sulfate concentration was explained by a model that considers sex, age and SLCO2B1/SLCO1B1 genotypes. Males are predicted to have 31% greater pregnenolone concentrations than females (p = 0.012) and increasing age significantly contributes to decreasing circulating levels (p < 0.0001). The SLCO1B1 c.388A>G variant did not associate with pregnenolone sulfate concentrations as previously found in univariate analysis when adjusting for other variables. Interestingly, SLCO2B1 c.1457C>T variant carriers continue to be associated with higher (45%, p = 0.014) pregnenolone sulfate concentrations with the multivariable model.
In the multivariable model for CPI, male sex is predicted to have 32% higher circulating concentrations than female sex (p = 0.006). Carriers of the SLCO2B1 c.935G>A variant are predicted to have 42% greater plasma CPI levels (p = 0.009). There was no longer a significant association with race that was found in the univariate analysis for CPI concentrations. Furthermore, the SLCO1B1 c.521T>C was not significantly associated with CPI levels. Altogether, approximately 27% of the variability in CPI could be explained by the model.
With the multivariable model for CPIII, female sex was significantly associated with lower CPIII concentrations by 22%. Again, race no longer was associated with circulating CPIII with multivariable regression analysis as was previously noted in the simple pairwise comparison. The SLCO2B1 c.935G>A variant is predicted to result in 31% greater plasma CPIII (p = 0.006), while possession of the SLCO2B1 c.917G>A variant was associated with 28% lower CPIII (p = 0.037). Approximately 35% of the variability in plasma CPIII could be explained by the model.
Discussion
OATP2B1 is considered an emerging transporter with clinical importance according to the International Transporter Consortium (Zamek-Gliszczynskiet al., 2018) and it has been argued that this transporter is deserving of greater attention (McFeely et al., 2019; Kinzi et al., 2021). Indeed, OATP2B1 seems to be involved in the oral absorption of medications and is the target of drug interactions in the intestine (McFeely et al., 2019; Medwid et al., 2019). Nevertheless, additional evidence to support or refute roles for OATP2B1 in drug disposition and in physiological functions is needed (Bednarczyk and Sanghvi, 2020; Kinzi et al., 2021). For several drug transporters such as OATP1B1, Organic Cation Transporter 1 (OCT1) and BCRP, the occurrence of functional genetic variations that influence drug and endobiotic disposition has helped to firmly establish their clinical relevance. But for OATP2B1, there have been many inconsistencies in the effects of common missense genetic variants on the plasma concentrations of presumed substrate drugs. Furthermore, the effects of these nonsynonymous genetic variants on OATP2B1 transport function in vitro have also been heterogeneous. The key limitations of studies that aim to determine a potential clinical role for OATP2B1 in drug disposition have been the lack of transporter-selective OATP2B1 substrates or inhibitors for use as pharmacological tools. Furthermore, it is possible that the in vivo pharmacokinetic effects of functional OATP2B1 genetic variations have been masked or complicated by the fact that altered transport activities in the gut that change oral drug bioavailability may be offset by impacts in other tissues that alter biodistribution and clearance.
In this report we aimed to provide additional insights into the functional consequences of relatively common genetic variants in OATP2B1/SLCO2B1 by examining potential impacts to endogenous substrate disposition both in vitro and in vivo. We have shown that the common OATP2B1 c.1457C>T variant has reduced transport activity towards a range of endogenous compounds and a prototypical drug. Importantly, we found associations with the SLCO2B1 c.935G>A variant with higher plasma concentrations of the endogenous substrates, CPI and CPIII, as well as with greater circulating pregnenolone sulfate levels in individuals carrying the SLCO2B1 c.1457C>T variant.
In transiently transfected cells, the OATP2B1 c.332G>A, c.601G>A, c.1457C>T variants had the most pronounced effects on OATP2B1 substrate transport, with decreased the cellular accumulation of estrone sulfate, DHEAS, CPI, CPIII and rosuvastatin compared to OATP2B1 wildtype (Figure 2). However, there were substrate-dependenteffects, particularly with the OATP2B1 c.601G>A variant. Reduced transport function of OATP2B1 c.332G>A, c.601G>A and c.1457C>T could be explained by their decreased cell surface expression of OATP2B1 (Figure 3). The OATP2B1 c.332G>A and the c.601G>A variants possessed the highest CADD/REVEL/MetaLR scores (Table 1) among the variants examined and are predicted to change amino acids near or within transmembrane spanning domains of OATP2B1 involved in the substrate translocation pore (Figure 1). Therefore, our results for these variants could be somewhat expected. In the context of previous studies, our observations are consistent with some that found reduced activity of the OATP2B1 c.332G>A and/or c.601G>A variants towards several substrates (Ho et al., 2006) but not with another report that observed no functional effects of the c.601G>Avariant (Nies et al., 2013). On the other hand, the OATP2B1 c.1457C>T variant results in a missense change in an amino acid residue in the large 5th extracellular loop and has a relatively low CADD/REVEL/MetaLR scores. However, we found that the OATP2B1 c.1457C>T variant had reduced transport function in vitro which was similar to other studies (Nozawa et al., 2002; Nies et al., 2013). But in contrast, two other studies found increased activity of OATP2B1 c.1457C>T (Ho et al., 2006; Yang et al., 2020). Lastly, we found that the most common OATP2B1 variant, namely c.935G>A, had rather benign functional consequences for substrates, except for a very slight reduction in rosuvastatin transport activity. Such a result would be in keeping with its low CADD/REVEL/MetaLR scores. However, our findings for the OATP2B1 c.935G>A variant contrast with others that find a reduction in transport function for some substrates (Yang et al., 2011; Nies et al., 2013; Yang et al., 2020).
There has been significant interest in circulating endogenous substrates of drug transporters and their potential utility as biomarkers of altered transporter activity. For instance, plasma concentrations of CPI, pyridoxic acid and N1-methylnicontinamide can serve to monitor the activities of OATP1B1/1B3, organic anion transporters (OATs) and organic cation transporters (OCTs), Multidrug And Toxin Extrusion (MATEs), respectively (Ito et al., 2012; Lai et al., 2016; Shen et al., 2019). Pharmacological inhibition or reduced function genetic polymorphisms of these drug transporters could result in elevated plasma concentrations of the endogenous biomarkers through a reduction in systemic clearance conferred by decreased transporter activities in the liver and kidney. Similarly for OATP2B1, we propose that higher concentrations of its endogenous substrates in circulation would signify reduced activity of a OATP2B1 genetic variant.
Estrone sulfate, the most abundant circulating estrogen, is taken up by cells from blood and converted to active estradiol for physiological endocrine function. Estrone sulfate is a well-studied substrate of OATP2B1, however it is also a substrate of many transporters including other OATPs, Na+-taurocholate co-transporting polypeptide (NTCP), OATs, organic solute transporter alpha-beta(OSTαβ), BCRP, and MRPs. Consequently, SLCO2B1 genetic variants were not associated with estrone sulfate plasma concentrations in our cohort of healthy volunteers. This is despite that there was reduced estrone sulfate transport activity with the OATP2B1 c.1457C>T variant in vitro and that 17 of 93 participants in the study carried this allele (5 homozygote, 12 heterozygote). However, we did confirm greater estrone sulfate concentrations in individuals with the SLCO1B1 c.521T>C allele as was previously reported (van der Deure et al., 2008). But the multivariate model for plasma estrone sulfate concentrations was not particularly effective in explaining interindividual variability (R2 = 0.047) indicating other genetic and biological factors are important (Platia et al., 1984; Feofanova et al., 2020).
DHEAS and pregnenolone sulfate are circulating sex steroid precursors of androgens and progesterone that are synthesized in the adrenal glands. Intact DHEAS and pregnenolone sulfate are neurosteroid hormones that functionally interact with neurotransmitter receptors and ion channels in the central nervous system (Grube et al., 2018). We observed the well-known and strong relationships between sex and age with plasma DHEAS and pregnenolone sulfate concentrations (Orentreich et al., 1984). DHEAS and pregnenolone sulfate are substrates of similar membrane transporters as estrone sulfate. Indeed, DHEAS is a substrate of OATP1B1/1B3, although previous studies in healthy volunteers found that treatment with rifampin, a potent inhibitor of OATP1B1/1B3, did not affect plasma DHEAS levels (Shen et al., 2017; Takehara et al., 2017). Likewise, we did not find that the reduced function SLCO1B1 c.521C>T allele was associated with DHEAS (or pregnenolone sulfate) concentrations. But DHEAS and pregnenolone sulfate plasma levels were associated with the SLCO2B1 variant c.1457C>T in univariate analysis (Table 4). After multivariate regression including the factors of age and sex, DHEAS plasma levels were no longer associated with SLCO2B1 c.1457C>T. This may be due to the lower age for SLCO2B1 c.1457C>T carriers compared to those with wildtype SLCO2B1. However, with adjustment for age and sex, pregnenolone sulfate concentrations were still predicted to be higher in those carrying SLCO2B1 c.1457C>T alleles (Table 5). Higher plasma pregnenolone sulfate levels would be consistent with the generally reduced transport activity of the OATP2B1 c.1457C>T variant in our in vitro studies.
CPI and CPIII are by-products of heme synthesis that are cleared from the body by biliary and renal excretion, with elimination in bile being the predominant pathway. The hepatocyte uptake of both CPI and CPIII are determined by the actions of OATP1B1, OATP1B3 and OATP2B1, while efflux into bile and blood are dependent on MRP2 and MRP3, respectively (Moriondo et al., 2009; Bednarczyk and Boiselle, 2016; Shen et al., 2016; Kunze et al., 2018). It is notable that while CPI is a good substrate of both OATP1B1 and OATP1B3, it is poorly transported by OATP2B1 (Bednarczyk and Boiselle, 2016; Shen et al., 2016). On the other hand, CPIII is capably transported by OATP1B1, OATP1B3 and OATP2B1 (Bednarczyk and Boiselle, 2016). We also find that OATP2B1 more efficiently transports CPIII than CPI (Figure 2). Genetic mutations that cause combined deficiencies in OATP1B1/OATP1B3 (Rotor Syndrome), result in redirection of CPI and CPIII elimination from bile to urine and an increase in CPI/CPIII urinary ratio (Wolkoff et al., 1976; van de Steeg et al., 2012). Unlike CPI, basal CPIII concentrations in the blood do not appear to be associated with the reduced function SLCO1B1 c.521T>C allele (Yee et al., 2019). Based on this evidence, we speculated that although CPI and CPIII are both OATP2B1 substrates, circulating CPIII would be more sensitive to the impacts of OATP2B1 genetic variation.
In our cohort of healthy participants, we found that both CPI and CPIII plasma concentrations were significantly influenced by sex and race, but not age. Males had greater concentrations of CPI and CPIII than females by 31 and 28%, respectively. The sex dependency on circulating CPI was previously reported in a cohort of Japanese subjects (Mori et al., 2019) and is thought to be related to differences in synthesis rate (Takita et al., 2020). In univariate analyses, East Asians had greater concentrations of CPI and CPIII compared to Caucasians (Figure 4). However, with multivariable regression, race was no longer an independent predictor of circulating CPI and CPIII (Table 5). It is likely that other covariates, particularly the differing allelic frequencies of SLCO2B1 variants (c.917G>A, c.935G>A and c.1457C>T) between the subgroups of East Asians and Caucasians (Table 3), largely contributed to the observed racial differences in coproporphyrin concentrations.
The key novel findings of our study are that circulating concentrations of both CPI and CPIII are greater in individuals carrying the most common SLCO2B1 c.935G>A variant (Table 4). This association was maintained in multiple linear regression when adjusting for other covariates including sex, race, and SLCO1B1 genotype (Table 5). These results suggest that the SLCO2B1 c.935G>A variant is a reduced transport function allele in vivo. However, this notion is in contrast with the lack of significant functional effects of the OATP2B1 c.935G>A variant observed in vitro (Figure 2). We also found that the SLCO2B1 c.917G>A allele was associated with lower CPIII concentrations (Tables 4, 5). Again, this in vivo association was not consistent with our observations of no change in OATP2B1 c.917G>A transport activity in vitro (Figure 2). However, it must be cautioned that there were relatively few participants (5 out of 93) with the SLCO2B1 c.917G>A variant. Another unexpected finding was that the SLCO2B1 c.935G>A variant was associated with higher plasma CPI concentrations given that CPI is a relatively poor substrate of OATP2B1 and that the absolute hepatic expression of OATP2B1 is approximately one-third of the more efficient CPI transporter, OATP1B1 (Badee et al., 2015). Additionally, we found CPI plasma concentrations were similar between SLCO1B1 wildtype and SLCO1B1 c.521T>C variant carriers (TC and CC genotypes), despite other studies having reported increased CPI with the variant allele (Mori et al., 2019; Yee et al., 2019; Suzuki et al., 2021). This difference is likely due to the fact that only one study participant had the homozygous SLCO1B1 c.521CC genotype, which was previously noted to have the most prominent impacts on CPI levels (Yee et al., 2019; Suzuki et al., 2021). Taken together, our findings imply that both plasma CPI and CPIII are sensitive to alterations in OATP2B1 activity that would be manifest with the possession of functional genetic polymorphisms and during inhibitory drug interactions. It follows that variation in circulating CPI and CPIII concentrations may not distinguish alterations in OATP2B1 activity apart from those occurring for OATP1B1. Finally, it is tempting to speculate that assessment of renal clearance of CPIII could better serve as a selective measure of (renal) OATP2B1 activity since CPIII is highly secreted by the kidney (Lai et al., 2016; Feng et al., 2021), in contrast to CPI which is eliminated mostly by glomerular filtration, and OATP2B1 is expressed in the proximal tubules (Ferreira et al., 2018).
We focused on relatively common missense variants in OATP2B1 to evaluate potential impacts on transporter function both in vitro and in vivo. However, a recent analysis indicates that rare variation in the SLCO2B1 gene may account for 11.6% of functional variability in OATP2B1 (Zhang and Lauschke, 2019). Therefore, targeted in vitro biochemical evaluation of rare OATP2B1 variants and high-throughput, deep mutational scanning techniques (Zhang et al., 2021), together with case- and population-based association studies are necessary to provide a more complete understanding of the relevance of OATP2B1 genetic variation.
In conclusion, we found that basal circulating concentrations of several endogenous substrates of OATP2B1 were associated with common non-synonymous genetic variations in the transporter in healthy individuals. These genetic associations were poorly aligned with the observed functional activities of the OATP2B1 variants in vitro, as well as with predictions from in silico algorithms. Additional studies are required to establish whether endogenous substrates may serve as biomarkers of OATP2B1 activity.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics Statement
The studies involving human participants were reviewed and approved by the Human Subject Research Ethics Board, University of Western Ontario. The patients/participants provided their written informed consent to participate in this study.
Author Contributions
SM, HP, DT, JM, and RT performed the experiments. SM, US, RK, and RT were involved in study design. SM and RT drafted the manuscript. All authors reviewed the draft and final manuscript.
Funding
This research was supported by the Canadian Institutes of Health Research project grant MOP-136909 (to R.G.T.).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.713567/full#supplementary-material
References
Ahlin, G., Hilgendorf, C., Karlsson, J., Szigyarto, C. A., Uhlén, M., and Artursson, P. (2009). Endogenous Gene and Protein Expression of Drug-Transporting Proteins in Cell Lines Routinely Used in Drug Discovery Programs. Drug Metab. Dispos. 37 (12), 2275–2283. doi:10.1124/dmd.109.028654
Akamine, Y., Miura, M., Sunagawa, S., Kagaya, H., Yasui-Furukori, N., and Uno, T. (2010). Influence of Drug-Transporter Polymorphisms on the Pharmacokinetics of Fexofenadine Enantiomers. Xenobiotica 40 (11), 782–789. doi:10.3109/00498254.2010.515318
Badée, J., Achour, B., Rostami-Hodjegan, A., and Galetin, A. (2015). Meta-analysis of Expression of Hepatic Organic Anion-Transporting Polypeptide (OATP) Transporters in Cellular Systems Relative to Human Liver Tissue. Drug Metab. Dispos. 43 (4), 424–432. doi:10.1124/dmd.114.062034
Bednarczyk, D., and Boiselle, C. (2016). Organic Anion Transporting Polypeptide (OATP)-mediated Transport of Coproporphyrins I and III. Xenobiotica 46 (5), 457–466. doi:10.3109/00498254.2015.1085111
Bednarczyk, D., and Sanghvi, M. V. (2020). Organic Anion Transporting Polypeptide 2B1 (OATP2B1), an Expanded Substrate Profile, Does it Align with OATP2B1's Hypothesized Function? Xenobiotica 50 (9), 1128–1137. doi:10.1080/00498254.2020.1745318
Chen, M., Hu, S., Li, Y., Gibson, A. A., Fu, Q., Baker, S. D., et al. (2020). Role of OATP2B1 in Drug Absorption and Drug-Drug Interactions. Drug Metab. Dispos. 48, 420–426. doi:10.1124/dmd.119.090316
DeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y. H., Dresser, G. K., Suskin, N., et al. (2013). Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. Circ. Cardiovasc. Genet. 6 (4), 400–408. doi:10.1161/CIRCGENETICS.113.000099
Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., et al. (2002). Fruit Juices Inhibit Organic Anion Transporting Polypeptide-Mediated Drug Uptake to Decrease the Oral Availability of Fexofenadine. Clin. Pharmacol. Ther. 71 (1), 11–20. doi:10.1067/mcp.2002.121152
Dudenkov, T. M., Ingle, J. N., Buzdar, A. U., Robson, M. E., Kubo, M., Ibrahim-Zada, I., et al. (2017). SLCO1B1 Polymorphisms and Plasma Estrone Conjugates in Postmenopausal Women with ER+ Breast Cancer: Genome-wide Association Studies of the Estrone Pathway. Breast Cancer Res. Treat. 164 (1), 189–199. doi:10.1007/s10549-017-4243-3
Feng, S., Bo, Q., Coleman, H. A., Charoin, J. E., Zhu, M., Xiao, J., et al. (2021). Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B. J. Clin. Pharmacol. 61, 1027–1034. doi:10.1002/jcph.1817
Feofanova, E. V., Chen, H., Dai, Y., Jia, P., Grove, M. L., Morrison, A. C., et al. (2020). A Genome-wide Association Study Discovers 46 Loci of the Human Metabolome in the Hispanic Community Health Study/Study of Latinos. Am. J. Hum. Genet. 107 (5), 849–863. doi:10.1016/j.ajhg.2020.09.003
Ferreira, C., Hagen, P., Stern, M., Hussner, J., Zimmermann, U., Grube, M., et al. (2018). The Scaffold Protein PDZK1 Modulates Expression and Function of the Organic Anion Transporting Polypeptide 2B1. Eur. J. Pharm. Sci. 120, 181–190. doi:10.1016/j.ejps.2018.05.006
Fujimoto, N., Kubo, T., Inatomi, H., Bui, H. T., Shiota, M., Sho, T., et al. (2013). Polymorphisms of the Androgen Transporting Gene SLCO2B1 May Influence the Castration Resistance of Prostate Cancer and the Racial Differences in Response to Androgen Deprivation. Prostate Cancer Prostatic Dis. 16 (4), 336–340. doi:10.1038/pcan.2013.23
Grube, M., Hagen, P., and Jedlitschky, G. (2018). Neurosteroid Transport in the Brain: Role of ABC and SLC Transporters. Front. Pharmacol. 9, 354. doi:10.3389/fphar.2018.00354
Grube, M., Köck, K., Karner, S., Reuther, S., Ritter, C. A., Jedlitschky, G., et al. (2006a). Modification of OATP2B1-Mediated Transport by Steroid Hormones. Mol. Pharmacol. 70 (5), 1735–1741. doi:10.1124/mol.106.026450
Grube, M., Köck, K., Oswald, S., Draber, K., Meissner, K., Eckel, L., et al. (2006b). Organic Anion Transporting Polypeptide 2B1 Is a High-Affinity Transporter for Atorvastatin and Is Expressed in the Human Heart. Clin. Pharmacol. Ther. 80 (6), 607–620. doi:10.1016/j.clpt.2006.09.010
Hahn, A. W., Gill, D. M., Poole, A., Nussenzveig, R. H., Wilson, S., Farnham, J. M., et al. (2019). Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-Onset Metastatic Castration-Resistant Prostate Cancer (mCRPC). Mol. Cancer Ther. 18 (3), 726–729. doi:10.1158/1535-7163.MCT-18-0739
Hirvensalo, P., Tornio, A., Neuvonen, M., Kiander, W., Kidron, H., Paile-Hyvärinen, M., et al. (2019). Enantiospecific Pharmacogenomics of Fluvastatin. Clin. Pharmacol. Ther. 106 (3), 668–680. doi:10.1002/cpt.1463
Ho, R. H., Leake, B. F., Kim, R. B., and Wang, Y. (2006). OATP2B1 Allelic Variants Differentially Transport Rosuvastatin In Vitro. Drug Metab. Rev. 38, 240–241. doi:10.1080/03602530600914867
Hussner, J., Begunk, R., Boettcher, K., Gliesche, D. G., Prestin, K., and Meyer Zu Schwabedissen, H. E. (2015). Expression of OATP2B1 as Determinant of Drug Effects in the Microcompartment of the Coronary Artery. Vascul Pharmacol. 72, 25–34. doi:10.1016/j.vph.2015.06.006
Ieiri, I., Doi, Y., Maeda, K., Sasaki, T., Kimura, M., Hirota, T., et al. (2012). Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose. J. Clin. Pharmacol. 52 (7), 1078–1089. doi:10.1177/0091270011408612
Imanaga, J., Kotegawa, T., Imai, H., Tsutsumi, K., Yoshizato, T., Ohyama, T., et al. (2011). The Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics of Fexofenadine and Midazolam in Humans. Pharmacogenet Genomics 21 (2), 84–93. doi:10.1097/fpc.0b013e32834300cc
Ito, S., Kusuhara, H., Kumagai, Y., Moriyama, Y., Inoue, K., Kondo, T., et al. (2012). N-methylnicotinamide Is an Endogenous Probe for Evaluation of Drug-Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2-K). Clin. Pharmacol. Ther. 92 (5), 635–641. doi:10.1038/clpt.2012.138
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., et al. (2020). The Mutational Constraint Spectrum Quantified from Variation in 141,456 Humans. Nature 581 (7809), 434–443. doi:10.1038/s41586-020-2308-7
Kashihara, Y., Ieiri, I., Yoshikado, T., Maeda, K., Fukae, M., Kimura, M., et al. (2017). Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J. Pharm. Sci. 106 (9), 2688–2694. doi:10.1016/j.xphs.2017.03.010
Kim, K. A., Lee, H. M., Joo, H. J., Park, I. B., and Park, J. Y. (2013). Effects of Polymorphisms of the SLCO2B1 Transporter Gene on the Pharmacokinetics of Montelukast in Humans. J. Clin. Pharmacol. 53 (11), 1186–1193. doi:10.1002/jcph.144
Kim, M., Deacon, P., Tirona, R. G., Kim, R. B., Pin, C. L., Meyer Zu Schwabedissen, H. E., et al. (2017a). Characterization of OATP1B3 and OATP2B1 Transporter Expression in the Islet of the Adult Human Pancreas. Histochem. Cel. Biol. 148 (4), 345–357. doi:10.1007/s00418-017-1580-6
Kim, T. E., Shin, D., Gu, N., Jung, B. H., Kim, J., Cho, Y. M., et al. (2017b). The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein. Basic Clin. Pharmacol. Toxicol. 121 (3), 195–201. doi:10.1111/bcpt.12826
Kinzi, J., Grube, M., and Meyer Zu Schwabedissen, H. E. (2021). OATP2B1 - The Underrated Member of the Organic Anion Transporting Polypeptide Family of Drug Transporters? Biochem. Pharmacol. 188, 114534. doi:10.1016/j.bcp.2021.114534
Knauer, M. J., Urquhart, B. L., Meyer zu Schwabedissen, H. E., Schwarz, U. I., Lemke, C. J., Leake, B. F., et al. (2010). Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins. Circ. Res. 106 (2), 297–306. doi:10.1161/CIRCRESAHA.109.203596
Kobayashi, D., Nozawa, T., Imai, K., Nezu, J., Tsuji, A., and Tamai, I. (2003). Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-dependent Transport across Intestinal Apical Membrane. J. Pharmacol. Exp. Ther. 306 (2), 703–708. doi:10.1124/jpet.103.051300
Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., et al. (2001). Organic Anion-Transporting Polypeptide B (OATP-B) and its Functional Comparison with Three Other OATPs of Human Liver. Gastroenterology 120 (2), 525–533. doi:10.1053/gast.2001.21176
Kunze, A., Ediage, E. N., Dillen, L., Monshouwer, M., and Snoeys, J. (2018). Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions. Clin. Pharmacokinet. 57 (12), 1559–1570. doi:10.1007/s40262-018-0648-3
Lai, Y., Mandlekar, S., Shen, H., Holenarsipur, V. K., Langish, R., Rajanna, P., et al. (2016). Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. J. Pharmacol. Exp. Ther. 358 (3), 397–404. doi:10.1124/jpet.116.234914
Lilja, J. J., Backman, J. T., Laitila, J., Luurila, H., and Neuvonen, P. J. (2003). Itraconazole Increases but Grapefruit Juice Greatly Decreases Plasma Concentrations of Celiprolol. Clin. Pharmacol. Ther. 73 (3), 192–198. doi:10.1067/mcp.2003.26
SEARCH Collaborative Group Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., et al. (2008). SLCO1B1 Variants and Statin-Induced Myopathy-Aa Genomewide Study. N. Engl. J. Med. 359 (8), 789–799. doi:10.1056/NEJMoa0801936
McFeely, S. J., Wu, L., Ritchie, T. K., and Unadkat, J. (2019). Organic Anion Transporting Polypeptide 2B1 - More Than a Glass-Full of Drug Interactions. Pharmacol. Ther. 196, 204–215. doi:10.1016/j.pharmthera.2018.12.009
McLean, C. C., Teft, W. A., Morse, B. L., Gryn, S. E., Hegele, R. A., and Kim, R. B. (2018). Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol. Clin. Pharmacol. Ther. 104 (3), 525–533. doi:10.1002/cpt.973
Medwid, S., Li, M. M. J., Knauer, M. J., Lin, K., Mansell, S. E., Schmerk, C. L., et al. (2019). Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. Drug Metab. Dispos. 47 (8), 832–842. doi:10.1124/dmd.119.087619
Meyer Zu Schwabedissen, H. E., Ferreira, C., Schaefer, A. M., Oufir, M., Seibert, I., Hamburger, M., et al. (2018). Thyroid Hormones Are Transport Substrates and Transcriptional Regulators of Organic Anion Transporting Polypeptide. Mol. Pharmacol. 94, 700. doi:10.1124/mol.117.111161
Mori, D., Kashihara, Y., Yoshikado, T., Kimura, M., Hirota, T., Matsuki, S., et al. (2019). Effect of OATP1B1 Genotypes on Plasma Concentrations of Endogenous OATP1B1 Substrates and Drugs, and Their Association in Healthy Volunteers. Drug Metab. Pharmacokinet. 34 (1), 78–86. doi:10.1016/j.dmpk.2018.09.003
Moriondo, V., Marchini, S., Di Gangi, P., Ferrari, M. C., Nascimbeni, F., Rocchi, E., et al. (2009). Role of Multidrug-Resistance Protein 2 in Coproporphyrin Transport: Results from Experimental Studies in Bile Fistula Rat Models. Cel. Mol. Biol. (Noisy-le-grand) 55 (2), 70–78. doi:10.1170/T855
Mougey, E. B., Feng, H., Castro, M., Irvin, C. G., and Lima, J. J. (2009). Absorption of Montelukast Is Transporter Mediated: a Common Variant of OATP2B1 Is Associated with Reduced Plasma Concentrations and Poor Response. Pharmacogenet Genomics 19 (2), 129–138. doi:10.1097/FPC.0b013e32831bd98c
Mougey, E. B., Lang, J. E., Wen, X., and Lima, J. J. (2011). Effect of Citrus Juice and SLCO2B1 Genotype on the Pharmacokinetics of Montelukast. J. Clin. Pharmacol. 51 (5), 751–760. doi:10.1177/0091270010374472
Müller, F., Sharma, A., König, J., and Fromm, M. F. (2018). Biomarkers for In Vivo Assessment of Transporter Function. Pharmacol. Rev. 70 (2), 246–277. doi:10.1124/pr.116.013326
Nakano, T., Katsuki, S., Chen, M., Decano, J. L., Halu, A., Lee, L. H., et al. (2019). Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation via the Interplay of OATP2B1 and Dll4-Notch Signaling. Circulation 139 (1), 78–96. doi:10.1161/CIRCULATIONAHA.118.034588
Niemi, M., Pasanen, M. K., and Neuvonen, P. J. (2011). Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacol. Rev. 63 (1), 157–181. doi:10.1124/pr.110.002857
Nies, A. T., Niemi, M., Burk, O., Winter, S., Zanger, U. M., Stieger, B., et al. (2013). Genetics Is a Major Determinant of Expression of the Human Hepatic Uptake Transporter OATP1B1, but Not of OATP1B3 and OATP2B1. Genome Med. 5 (1), 1. doi:10.1186/gm405
Niessen, J., Jedlitschky, G., Grube, M., Bien, S., Schwertz, H., Ohtsuki, S., et al. (2009). Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin. Drug Metab. Dispos. 37 (5), 1129–1137. doi:10.1124/dmd.108.024570
Nozawa, T., Imai, K., Nezu, J., Tsuji, A., and Tamai, I. (2004). Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human. J. Pharmacol. Exp. Ther. 308 (2), 438–445. doi:10.1124/jpet.103.060194
Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J., Sai, Y., et al. (2002). Genetic Polymorphisms of Human Organic Anion Transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele Frequencies in the Japanese Population and Functional Analysis. J. Pharmacol. Exp. Ther. 302 (2), 804–813. doi:10.1124/jpet.302.2.804
Orentreich, N., Brind, J. L., Rizer, R. L., and Vogelman, J. H. (1984). Age Changes and Sex Differences in Serum Dehydroepiandrosterone Sulfate Concentrations throughout Adulthood. J. Clin. Endocrinol. Metab. 59 (3), 551–555. doi:10.1210/jcem-59-3-551
Pizzagalli, F., Varga, Z., Huber, R. D., Folkers, G., Meier, P. J., and St-Pierre, M. V. (2003). Identification of Steroid Sulfate Transport Processes in the Human Mammary Gland. J. Clin. Endocrinol. Metab. 88 (8), 3902–3912. doi:10.1210/jc.2003-030174
Platia, M. P., Fencl, M. D., Elkind-Hirsch, K. E., Canick, J. A., and Tulchinsky, D. (1984). Estrone Sulfatase Activity in the Human Brain and Estrone Sulfate Levels in the normal Menstrual Cycle. J. Steroid Biochem. 21 (3), 237–241. doi:10.1016/0022-4731(84)90275-9
Rodrigues, D., and Rowland, A. (2019). From Endogenous Compounds as Biomarkers to Plasma-Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational Pharmacokinetics-Absorption, Distribution, Metabolism, Excretion-Drug-Drug Interaction Science Finally Arrived? Clin. Pharmacol. Ther. 105 (6), 1407–1420. doi:10.1002/cpt.1328
Seki, S., Kobayashi, M., Itagaki, S., Hirano, T., and Iseki, K. (2009). Contribution of Organic Anion Transporting Polypeptide OATP2B1 to Amiodarone Accumulation in Lung Epithelial Cells. Biochim. Biophys. Acta 1788 (5), 911–917. doi:10.1016/j.bbamem.2009.03.003
Shen, H., Chen, W., Drexler, D. M., Mandlekar, S., Holenarsipur, V. K., Shields, E. E., et al. (2017). Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects. Drug Metab. Dispos. 45 (8), 908–919. doi:10.1124/dmd.117.075531
Shen, H., Dai, J., Liu, T., Cheng, Y., Chen, W., Freeden, C., et al. (2016). Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species. J. Pharmacol. Exp. Ther. 357 (2), 382–393. doi:10.1124/jpet.116.232066
Shen, H., Holenarsipur, V. K., Mariappan, T. T., Drexler, D. M., Cantone, J. L., Rajanna, P., et al. (2019). Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. J. Pharmacol. Exp. Ther. 368 (1), 136–145. doi:10.1124/jpet.118.252643
St-Pierre, M. V., Hagenbuch, B., Ugele, B., Meier, P. J., and Stallmach, T. (2002). Characterization of an Organic Anion-Transporting Polypeptide (OATP-B) in Human Placenta. J. Clin. Endocrinol. Metab. 87 (4), 1856–1863. doi:10.1210/jcem.87.4.8431
Suzuki, Y., Sasamoto, Y., Koyama, T., Yoshijima, C., Nakatochi, M., Kubo, M., et al. (2021). Substantially Increased Plasma Coproporphyrin-I Concentrations Associated with OATP1B1*15 Allele in Japanese General Population. Clin. Transl. Sci. 14 (1), 382–388. doi:10.1111/cts.12889
Takehara, I., Terashima, H., Nakayama, T., Yoshikado, T., Yoshida, M., Furihata, K., et al. (2017). Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers. Pharm. Res. 34 (8), 1601–1614. doi:10.1007/s11095-017-2184-5
Takita, H., Barnett, S., Zhang, Y., Ménochet, K., Shen, H., Ogungbenro, K., et al. (2021). PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability. CPT Pharmacometrics Syst. Pharmacol. 10, 137–147. doi:10.1002/psp4.12582
Tamai, I., Nezu, J., Uchino, H., Sai, Y., Oku, A., Shimane, M., et al. (2000). Molecular Identification and Characterization of Novel Members of the Human Organic Anion Transporter (OATP) Family. Biochem. Biophys. Res. Commun. 273 (1), 251–260. doi:10.1006/bbrc.2000.2922
Tapaninen, T., Karonen, T., Backman, J. T., Neuvonen, P. J., and Niemi, M. (2013). SLCO2B1 c.935G>A Single Nucleotide Polymorphism Has No Effect on the Pharmacokinetics of Montelukast and Aliskiren. Pharmacogenet Genomics 23 (1), 19–24. doi:10.1097/FPC.0b013e32835bac90
Tirona, R. G., Kassam, Z., Strapp, R., Ramu, M., Zhu, C., Liu, M., et al. (2018). Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. Drug Metab. Dispos. 46, 485–492. doi:10.1124/dmd.117.079624
Tirona, R. G., Leake, B. F., Merino, G., and Kim, R. B. (2001). Polymorphisms in OATP-C: Identification of Multiple Allelic Variants Associated with Altered Transport Activity Among European- and African-Americans. J. Biol. Chem. 276 (38), 35669–35675. doi:10.1074/jbc.M103792200
Tirona, R. G., Leake, B. F., Wolkoff, A. W., and Kim, R. B. (2003). Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation. J. Pharmacol. Exp. Ther. 304 (1), 223–228. doi:10.1124/jpet.102.043026
Treviño, L. R., Shimasaki, N., Yang, W., Panetta, J. C., Cheng, C., Pei, D., et al. (2009). Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated with Methotrexate Pharmacokinetics and Clinical Effects. J. Clin. Oncol. 27 (35), 5972–5978. doi:10.1200/JCO.2008.20.4156
van de Steeg, E., Stránecký, V., Hartmannová, H., Nosková, L., Hřebíček, M., Wagenaar, E., et al. (2012). Complete OATP1B1 and OATP1B3 Deficiency Causes Human Rotor Syndrome by Interrupting Conjugated Bilirubin Reuptake into the Liver. J. Clin. Invest. 122 (2), 519–528. doi:10.1172/JCI59526
van der Deure, W. M., Friesema, E. C., de Jong, F. J., de Rijke, Y. B., de Jong, F. H., Uitterlinden, A. G., et al. (2008). Organic Anion Transporter 1B1: an Important Factor in Hepatic Thyroid Hormone and Estrogen Transport and Metabolism. Endocrinology 149 (9), 4695–4701. doi:10.1210/en.2008-0169
Wang, X., Harshman, L. C., Xie, W., Nakabayashi, M., Qu, F., Pomerantz, M. M., et al. (2016). Association of SLCO2B1 Genotypes with Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. J. Clin. Oncol. 34 (4), 352–359. doi:10.1200/JCO.2015.62.5988
Wolkoff, A. W., Wolpert, E., Pascasio, F. N., and Arias, I. M. (1976). Rotor's Syndrome. A Distinct Inheritable Pathophysiologic Entity. Am. J. Med. 60 (2), 173–179. doi:10.1016/0002-9343(76)90426-5
Woolsey, S. J., Beaton, M. D., Choi, Y. H., Dresser, G. K., Gryn, S. E., Kim, R. B., et al. (2016). Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. Basic Clin. Pharmacol. Toxicol. 118 (4), 284–291. doi:10.1111/bcpt.12492
Yang, J., Wang, Z., Liu, S., Wang, W., Zhang, H., and Gui, C. (2020). Functional Characterization Reveals the Significance of Rare Coding Variations in Human Organic Anion Transporting Polypeptide 2B1 (SLCO2B1). Mol. Pharm. 17 (10), 3966–3978. doi:10.1021/acs.molpharmaceut.0c00747
Yang, M., Xie, W., Mostaghel, E., Nakabayashi, M., Werner, L., Sun, T., et al. (2011). SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. J. Clin. Oncol. 29 (18), 2565–2573. doi:10.1200/JCO.2010.31.2405
Yee, S. W., Brackman, D. J., Ennis, E. A., Sugiyama, Y., Kamdem, L. K., Blanchard, R., et al. (2018). Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective from the International Transporter Consortium. Clin. Pharmacol. Ther. 104 (5), 803–817. doi:10.1002/cpt.1098
Yee, S. W., Giacomini, M. M., Shen, H., Humphreys, W. G., Horng, H., Brian, W., et al. (2019). Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. Clin. Transl. Sci. 12 (4), 388–399. doi:10.1111/cts.12625
Zamek-Gliszczynski, M. J., Taub, M. E., Chothe, P. P., Chu, X., Giacomini, K. M., Kim, R. B., et al. (2018). Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clin. Pharmacol. Ther. 104 (5), 890–899. doi:10.1002/cpt.1112
Zhai, G., Teumer, A., Stolk, L., Perry, J. R., Vandenput, L., Coviello, A. D., et al. (2011). Eight Common Genetic Variants Associated with Serum DHEAS Levels Suggest a Key Role in Ageing Mechanisms. Plos Genet. 7 (4), e1002025. doi:10.1371/journal.pgen.1002025
Zhang, B., and Lauschke, V. M. (2019). Genetic Variability and Population Diversity of the Human SLCO (OATP) Transporter Family. Pharmacol. Res. 139, 550–559. doi:10.1016/j.phrs.2018.10.017
Keywords: drug transporter, genetic variant, endogenous substrates, organic anion transporting polypeptide 2B1 (OATP2B1), pharmacogenenomics and personalised medicine
Citation: Medwid S, Price HR, Taylor DP, Mailloux J, Schwarz UI, Kim RB and Tirona RG (2021) Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates. Front. Pharmacol. 12:713567. doi: 10.3389/fphar.2021.713567
Received: 23 May 2021; Accepted: 23 August 2021;
Published: 14 September 2021.
Edited by:
Caroline Flora Samer, Geneva University Hospitals (HUG), SwitzerlandReviewed by:
Volker Martin Lauschke, Karolinska Institutet (KI), SwedenBo Liu, Sichuan University, China
Copyright © 2021 Medwid, Price, Taylor, Mailloux, Schwarz, Kim and Tirona. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rommel G. Tirona, rommel.tirona@schulich.uwo.ca